Viatris (VTRS) to acquire Pacira BioSciences (PCRX) at $36.50/share cash — Thu Oct 8 definitive agreement, ~<meta name="viewport" content="width=device-width, initial-scale=1.0" />.65B equity value, ~44.8% premium to Tue Oct 7 close of $25.20; 10-business-day tender offer, expected to close by end of 2026; PCRX +~44% to ~$36.31; VTRS -1.1% to <meta name="viewport" content="width=device-width, initial-scale=1.0" />7.29

.65B." /> .65B equity value, ~44.8% premium to Tue Oct 7 close of $25.20; 10-business-day tender offer, expected to close by end of 2026; PCRX +~44% to ~$36.31; VTRS -1.1% to 7.29" /> .65B." /> .65B equity value, ~44.8% premium to Tue Oct 7 close of $25.20; 10-business-day tender offer, expected to close by end of 2026; PCRX +~44% to ~$36.31; VTRS -1.1% to 7.29" /> .65B." />

Stock/TLDR — What Just Moved Markets: Earnings, Fed, M&A, MoversA high-volume feed of market-moving releases — quarterly earnings, FOMC decisions, M&A, regulatory actions, big single-name moves, macro prints, commodities and crypto — refreshed every 12 hours. Each release is explained in plain English so you actually understand what just happened and which tickers it touches.This site uses JavaScript to render the interactive feed. Enable JavaScript to use it.Stock/TLDR is not investment advice. Verify everything against primary sources before trading.